Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China

Abstract

This study aims to assess the risk factors of cardiovascular disease (CVD) and to determine the association of traditional and biologic disease-modifying anti-rheumatic drugs (DMARDs) with risk for CVD in Chinese rheumatoid arthritis (RA) patients. A cross-sectional cohort of 2013 RA patients from 21 hospitals around China was established. Medical history of CVD was documented. The patients’ social background, clinical manifestations, comorbidities, and medications were also collected. Of the 2013 patients, 256 had CVD with an incidence of 12.7%. Compared with non-CVD controls, RA patients with CVD had a significantly advanced age, long-standing median disease duration, more often male and more deformity joints. Patients with CVD also had higher rates of smoking, rheumatoid nodules, interstitial lung disease, and anemia. The prevalence of comorbidities, including hypothyroidism, diabetes mellitus (DM), hypertension, and hyperlipidemia, was also significant higher in the CVD group. In contrast, patients treated with methotrexate, hydroxychloroquine (HCQ), and TNF blockers had lower incidence of CVD. The multivariate analysis showed that the use of HCQ was a protective factor of CVD, while hypertension, hyperlipidemia, and interstitial lung disease were independent risk factors of CVD. Our study shows that the independent risk factors of CVD include hypertension, hyperlipidemia, and interstitial lung disease. HCQ reduces the risk of CVD in patients with RA.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26:S35–S61

  2. 2.

    Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, Matteson EL (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58

  3. 3.

    Gonzalez A, Maradit KH, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O’Fallon WM, Gabriel SE (2008) Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients. Ann Rheum Dis 67:64–69

  4. 4.

    Pham T, Gossec L, Constantin A, Pavy S, Bruckert E, Cantagrel A, Combe B, Flipo RM, Goupille P, Le LX, Mariette X, Puechal X, Schaeverbeke T, Sibilia J, Tebib J, Wendling D, Dougados M (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73:379–387

  5. 5.

    Restrepo JF, Del RI, Battafarano DF, Haas RW, Doria M, Escalante A (2015) Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol 34(9):1529–1536

  6. 6.

    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331

  7. 7.

    Crowson CS, Gabriel SE (2011) Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis 70:719–721

  8. 8.

    Dessein PH, Semb AG (2013) Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced. Ann Rheum Dis 72:1743–1746

  9. 9.

    Arts EE, Popa C, Den BAA, Semb AG, Toms T, Kitas GD, van Riel PL, Fransen J (2014) Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 74:668–674

  10. 10.

    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151

  11. 11.

    Avouac J, Allanore Y (2008) Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 9:1121–1128

  12. 12.

    Bili A, Tang X, Pranesh S, Bozaite R, DO SJ, Antohe JL, Kirchner HL, Wasko MC (2013) TNF-alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66:355–363.

  13. 13.

    Davis JM 3rd, Maradit KH, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56:820–830

  14. 14.

    Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, Vazquez-Rodriguez TR, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA (2011) TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216:125–130

  15. 15.

    van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, Stehouwer CD, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Dijkmans BA, Nurmohamed MT (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68:1395–1400

  16. 16.

    (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413–2446

  17. 17.

    Bobbio-Pallavicini F, Caporali R, Bugatti S, Montecucco C (2008) What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies. J Rheumatol 35:1903–1905

  18. 18.

    World Health Organization Western Pacific Region/IASO/IOTF (2000) The Asia–Pacific perspective: redefining obesity and its treatment. Sydney

  19. 19.

    Goodson NJ, Farragher TM, Symmons DP (2008) Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. J Rheumatol 35:945–949

  20. 20.

    Erb N, Pace AV, Douglas KM, Banks MJ, Kitas GD (2004) Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 33:293–299

  21. 21.

    Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, Symmons DP, Nightingale P, Metsios GS, Kitas GD (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk. Ann Rheum Dis 69:683–688

  22. 22.

    Steiner G, Urowitz MB (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 38:372–381

  23. 23.

    Sandoo A, Chanchlani N, Hodson J, Smith JP, Douglas KM, Kitas GD (2013) Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. Arthritis Res Ther 15:R203

  24. 24.

    Chung CP, Giles JT, Kronmal RA, Post WS, Gelber AC, Petri M, Szklo M, Detrano R, Budoff MJ, Blumenthal RS, Ouyang P, Bush D, Bathon JM (2013) Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther 15:R134

  25. 25.

    Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, Dixey J, Gough A, Prouse P, Winfield J, Williams P (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 49:1483–1489

  26. 26.

    Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, Bili A (2011) Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63:530–534

  27. 27.

    Anigbogu CN, Adigun SA, Inyang I, Adegunloye BJ (1993) Chloroquine reduces blood pressure and forearm vascular resistance and increases forearm blood flow in healthy young adults. Clin Physiol 13:209–216

  28. 28.

    Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136–1142

  29. 29.

    Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54:2765–2775

  30. 30.

    Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, Giugliano D (1990) Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug. Ann Intern Med 112:678–681

  31. 31.

    Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22

  32. 32.

    Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM (2007) Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298:187–193

  33. 33.

    Weissberg PL, Bennett MR (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:1928–1929

  34. 34.

    Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480–489

  35. 35.

    Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med 126(730):e9-730–e9-e17

  36. 36.

    Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M (2012) No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford) 51:1107–1111

  37. 37.

    Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469

  38. 38.

    Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS (2015) An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol 67:372–380

  39. 39.

    Ursini F, Russo E, Letizia HM, Mauro D, Savarino F, Bruno C, Tripolino C, Rubino M, Naty S, Grembiale RD (2015) Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 94:e888

  40. 40.

    Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824

  41. 41.

    Liao KP, Solomon DH (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 52:45–52

Download references

Acknowledgments

We are very grateful to the patients and their families for their cooperation and for giving consent to participate in this study.

Author information

Correspondence to Rong Mu or Z. G. Li.

Ethics declarations

The study was approved by the Ethics Committee of Peking University People’s Hospital, and informed written consents were obtained from all study participants (FWA00001384).

Disclosures

None.

Funding

Supported by National High Technology Research and Development Program of China (973 Program, 2012CB517700) and National Natural Science Foundation of China (NSFC, No. 81202297)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, C., Wang, X.R., Ji, H.J. et al. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol 36, 1023–1029 (2017). https://doi.org/10.1007/s10067-017-3596-7

Download citation

Keywords

  • Cardiovascular disease
  • Rheumatoid arthritis
  • Risk factor